Grifols (GRFS) Cash from Investing Activities (2010 - 2020)
Grifols (GRFS) reported Cash from Investing Activities of -$125.1 million for Q1 2020, up 56.61% on a YoY basis from -$79.9 million in Q2 2019, and up 71.26% quarter-over-quarter from -$435.2 million in Q4 2019.
Grifols (GRFS) Cash from Investing Activities (2010 - 2020) Analysis & Trends
Grifols has reported Cash from Investing Activities for 10 years, with the latest figure at -$125.1 million in Q1 2020.
- For the quarter ending Q1 2020, Cash from Investing Activities rose 56.61% year-over-year to -$125.1 million; the trailing twelve-month figure through Mar 2020 stood at -$94.3 million (down 223.87% YoY), and the FY2025 full-year result was -$674.0 million, down 171.19% from the prior year.
- Cash from Investing Activities for Q1 2020 stood at -$125.1 million, up from -$435.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $2.4 billion in Q4 2017, with the low at -$798.7 million in Q3 2016.
- Historically, Cash from Investing Activities has averaged $281.0 million across 5 years, with a median of -$120.2 million in 2016.
- Annual changes were most pronounced in 2016 — Cash from Investing Activities sank 1045.5% — and 2017, when it soared 2116.99%.
- Grifols' Cash from Investing Activities stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then plunged by 68.9% to $754.2 million in 2018, then slumped by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
- The last three Cash from Investing Activities figures came in at -$125.1 million (Q1 2020), -$435.2 million (Q4 2019), and -$288.3 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.98 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -125.09 Mn |
| Mar 31, 2020 | -125.09 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Dec 31, 2017 | 2.43 Bn |
| Dec 31, 2017 | 2.43 Bn |
| Jun 30, 2017 | 88.45 Mn |
| Jun 30, 2017 | 88.45 Mn |
| Mar 31, 2017 | 1.98 Bn |
| Mar 31, 2017 | 1.98 Bn |
| Dec 31, 2016 | -120.24 Mn |
| Dec 31, 2016 | -120.24 Mn |